These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25827165)

  • 1. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
    Eriksson L; Nyström T
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
    Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
    Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study.
    Li F; Zhao T; Wen X
    Diabetes Res Clin Pract; 2011 Nov; 94(2):186-92. PubMed ID: 21871685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B
    Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus.
    Swidan SZ; Montgomery PA
    Pharmacotherapy; 1998; 18(5):961-72. PubMed ID: 9758308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.
    Kaur R; Kaur M; Singh J
    Cardiovasc Diabetol; 2018 Aug; 17(1):121. PubMed ID: 30170601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug treatments to restore vascular function and diabesity.
    Cardillo C
    Ann Pharm Fr; 2013 Jan; 71(1):27-33. PubMed ID: 23348853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.
    Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
    J Intern Med; 2010 Jul; 268(1):75-82. PubMed ID: 20210844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
    Nyström T; Gutniak MK; Zhang Q; Zhang F; Holst JJ; Ahrén B; Sjöholm A
    Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1209-15. PubMed ID: 15353407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics.
    Ceriello A; Esposito K; Ihnat M; Thorpe J; Giugliano D
    Diabet Med; 2010 Aug; 27(8):911-7. PubMed ID: 20653749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.
    Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
    Bailey CJ
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.
    Hopkins ND; Cuthbertson DJ; Kemp GJ; Pugh C; Green DJ; Cable NT; Jones H
    Diabetes Obes Metab; 2013 Aug; 15(8):770-3. PubMed ID: 23451821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk.
    Levine JP
    J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.